Conference abstractPublished 22 Aug 2016
Limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis
Ain Shams University, Egypt
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The relative risk reduction ( RRR) is the main statistical parameter used to express the different primary outcomes of the clinical drug trials. Physicians often assume that a drug with a higher RRR demonstrated in one trial is more effective than a drug with a lower RRR demonstrated in another trial, and may pass this idea on to younger physicians and to the patients. The use-of the RRR as a measure of drug efficacy can be misleading as it depends on the nature of the population studied. The value of the RRR depends on the placebo event rate : A low RRR can be clinically meaningful if the event rate in the placebo group is high, while a high RRR can be clinically less meaningful if the event rate in the placebo group is low. Direct head to head comparison trials are the only way to assess the relative efficacy of the different drugs. The aim of this presentation is to correct this misconception.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Magd Zakaria”